Centre caps trade margins on non-scheduled cancer drugs at 30%, expects ₹2,500 crore annual savings for patients

What has the government changed about the prices of non-scheduled cancer medicines?

The government has approved a 30% cap on margins charged during the supply and sale of non-scheduled anti-cancer medicines. These medicines were outside the government’s list of drugs with fixed ceiling prices. The change matters because high margins can greatly increase cancer-treatment costs paid by patients and families.

The cap limits trade margins to 30% of a medicine’s maximum retail price, or MRP. The National Pharmaceutical Pricing Authority found an average mark-up of about 170%, with some cases reaching 700% or more. Prices also differed between retail, hospital and online pharmacies.

An expert committee under the Directorate General of Health Services will finalise the covered medicines. The NPPA will then issue the implementation notification. The government expects the measure to reduce prices by up to 70% and save patients ₹2,500 crore each year, while manufacturers must maintain current production levels.

What are non-scheduled medicines, and how are they different from scheduled medicines whose prices have government-set ceilings?

Non-scheduled medicines are drugs that are not included in the list subject to government-fixed ceiling prices. In this case, the term refers to anti-cancer medicines outside that price-control list. Their prices and trade margins were therefore not protected by the same ceiling-price system.

Scheduled medicines, by contrast, are covered by government-set ceiling prices. The article does not provide the full legal definition or complete list of scheduled medicines. It does establish the practical difference: scheduled drugs have government-fixed price ceilings, while non-scheduled cancer medicines previously did not.

The new policy extends price protection to non-scheduled anti-cancer medicines. It will cover branded and generic drugs, imported and domestically produced medicines, and patented and non-patented medicines. An expert committee will decide the list, after which the NPPA will notify the rule. This brings wider oversight without changing the medicines’ scheduled status.

How high are the current mark-ups on these medicines, and how much money does the government expect patients to save each year?

The National Pharmaceutical Pricing Authority found that non-scheduled anti-cancer medicines carry an average price mark-up of approximately 170%. In some cases, the mark-up reaches 700% or more. These figures show how sharply supply-chain additions can raise the amount paid for expensive cancer treatment.

The article does not give one fixed mark-up for every medicine. Instead, it reports an average and highlights extreme cases. Prices also vary depending on where patients buy the medicine: a retail pharmacy, a hospital pharmacy or an online pharmacy. The new policy targets these pricing problems by limiting margins.

The government estimates that the wider intervention will reduce prices by up to 70%. It expects annual savings of ₹2,500 crore for cancer patients. The estimate is a government projection, while the actual saving for each medicine will depend on its current price, mark-up and eventual coverage under the notified list.

How can limiting trade margins to 30% of MRP reduce the final price of a cancer medicine by as much as 70%?

A trade margin is the amount added as a medicine moves through supply and sale. If that addition is unusually large, the final price paid by a patient rises well above the underlying price. Limiting the margin to 30% reduces the room for distributors, hospitals or pharmacies to add large mark-ups.

For example, the NPPA found an average mark-up of about 170%, and some cases reached 700% or more. Under the new mechanism, the permitted margin would be limited to 30% of the medicine’s MRP. Cutting a much larger existing margin to that level can produce a major price reduction, although the exact reduction differs by product.

The government says prices could fall by up to 70%, not that every medicine will fall by that amount. Prices currently vary between retail, hospital and online pharmacies. The expert committee’s coverage list and the NPPA’s notification will determine how the rule applies in practice.

Which government bodies will decide which medicines are covered and enforce the new pricing rule?

Two government bodies have distinct roles in implementing the new pricing rule. An expert committee under the Directorate General of Health Services will first finalise the list of non-scheduled anti-cancer medicines covered by the intervention. This determines which products receive the new protection.

After the list is prepared, the National Pharmaceutical Pricing Authority, or NPPA, will take a decision and issue the notification implementing the measure. The notification is the step that formally puts the 30% trade-margin cap into operation for the covered medicines.

The policy is intended to cover medicines across several categories. These include branded and generic products, domestically produced and imported medicines, and patented and non-patented medicines. Manufacturers will also be required to maintain current production levels, an obligation the government says is intended to help prevent shortages as prices are controlled.

What happened when the government applied a 30% trade-margin cap to 42 non-scheduled cancer drugs in 2019?

In February 2019, the NPPA capped trade margins at 30% for 42 selected non-scheduled anti-cancer drugs. The action was taken under Paragraph 19 of the Drugs (Prices Control) Order, 2013. It was an earlier example of using margin controls to reduce prices for medicines outside the scheduled list.

According to the department, that intervention reduced maximum retail prices by up to 91%. The reductions applied across 526 brands. This result became an important reference point for the wider measure now approved, which targets non-scheduled anti-cancer medicines across categories rather than only the earlier selected group.

The 2019 decision reportedly produced annual savings of ₹984 crore. The government says the new policy builds on that experience and addresses wider supply-chain pricing problems. It also includes production requirements for manufacturers, as the government seeks to prevent shortages while extending price protection.

How do manufacturers, distributors, hospitals, pharmacies and patients interact in the medicine supply chain, and where can mark-ups be added?

Manufacturers produce the medicines, which then move through the supply chain before reaching patients. Distributors help supply sellers, while hospital pharmacies, retail pharmacies and online pharmacies sell medicines to patients. The article also identifies domestically produced and imported medicines, along with branded and generic products, within this wider market.

Mark-ups can be added during supply and sale. The article does not specify the exact amount added by manufacturers, distributors, hospitals or pharmacies individually. It reports that non-scheduled anti-cancer medicines have an average mark-up of approximately 170%, with some at 700% or more. Prices also vary by purchase location.

The new rule targets the combined trade margins on covered medicines, limiting them to 30% of MRP. Manufacturers must maintain current production levels. This aims to curb excessive profiteering and unfair pricing while reducing patients’ out-of-pocket treatment costs and avoiding shortages.

Key Facts:

📌 Trade margins on non-scheduled cancer medicines will be capped at 30%.

📌 The government expects prices to fall by up to 70%.

📌 Patients could save ₹2,500 crore annually.

📌 Non-scheduled medicines fall outside the government’s ceiling-price list.

📌 Scheduled medicines have government-fixed ceiling prices.

📌 The new measure extends price protection to non-scheduled cancer drugs.

📌 Average mark-ups are approximately 170%.